62 results
FWP
GOSS
Gossamer Bio Inc
30 Jan 19
Free writing prospectus
5:29pm
-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@baml.com; or from SVB Leerink, Attention: Syndicate Department, One … Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (888) 603-5847
FWP
GOSS
Gossamer Bio Inc
23 Jan 19
Free writing prospectus
8:26pm
Department, or by email at dg.prospectus_requests@baml.com; or from SVB Leerink, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston … , Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at(888) 603-5847, or by email at Barclaysprospectus
8-K
EX-99.1
GOSS
Gossamer Bio Inc
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
: Prospectus Department, or by email at dg.prospectus_requests@bofa.com or from SVB
Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th … senior notes offering, from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone
FWP
GOSS
Gossamer Bio Inc
18 May 20
Free writing prospectus
5:02pm
-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests … @bofa.com or from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at1-800-808-7525, ext
8-K
EX-99.2
GOSS
Gossamer Bio Inc
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com or from SVB Leerink LLC, Attention: Syndicate Department, One … to the convertible senior notes offering, from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402
8-K
fnxy7g7 yt4m0m8c
4 Mar 24
Other Events
4:02pm
FWP
y8o7 qx9vumq
19 May 20
Free writing prospectus
6:06am
8-K
EX-99.1
h8dnu
20 Apr 21
Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer
4:44pm
8-K
s3ig5q2fr5k
20 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:01pm
8-K
EX-1.2
6n66tvsn55vurn6umrhd
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-1.1
56k0c
21 May 20
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
4:06pm
8-K
EX-99.1
6qc86kda3q9gfc3uhf7
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
8-K
EX-99.2
lua1l7vjhdnqu 1ntk
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
S-1
EX-10.16
3izw2
21 Dec 18
IPO registration
4:39pm